ICH Topic E2A: Clinical Safety Data Management

This harmonised ICH tripartite guideline defines common terminology and operational standards for clinical safety data management in the investigational, pre‑marketing phase of medicinal product development. It harmonises how important clinical safety information is collected, assessed and reported so that regulators, sponsors and investigators can apply consistent Good Clinical Practice standards across regions. It also treats pre‑marketing and post‑marketing safety reporting as interdependent, while recognising that pharmacovigilance responsibilities may sit in different organisational units depending on whether a product is investigational or marketed.

The guideline provides a practical framework for compliant safety reporting procedures, including definitions of serious adverse events and adverse drug reactions, reporting timelines and criteria for expedited regulatory reporting. Users can start with Section II for definitions and seriousness criteria, then use Section III and Attachment 1 as a checklist when designing safety reporting workflows, case report forms and standard operating procedures.

Section I explains the rationale for harmonisation and links to earlier Council for International Organisations of Medical Sciences Working Group outputs on expedited reports and periodic safety update reporting.

Section II sets out terminology for adverse events, adverse drug reactions, unexpected adverse drug reactions and serious adverse events, including seriousness criteria (death, life‑threatening events, hospitalisation, disability or congenital anomaly) and the distinction between seriousness and severity.

Section III defines expedited reporting standards: what must be reported, which additional observations may require rapid communication, reporting time frames (fatal or life‑threatening cases within 7 days plus 8 days for follow‑up; other serious unexpected reactions within 15 days) and the minimum criteria before a case is submitted.

Additional guidance covers managing blinded therapy cases in double‑blind studies, handling reactions with active comparators or placebo, and dealing with products that have multiple dosage forms, formulations, indications or populations. It also addresses post‑study serious adverse events, sponsor responsibilities for updating the Investigator’s Brochure and informing investigators and research ethics committees or institutional review boards, and the key data elements needed for expedited reports, including patient identifiers, suspect medicinal product details, concomitant therapies, reaction description and timing, outcome and reporter and sponsor information.